Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 3, 2008, Pages

  Stoessel, Adelina ^a   Paliege, Alexander ^a   Theilig, Franziska ^a   Addabbo, Francesco ^c   Ratliff, Brian ^c   Waschke, Jens ^b   Patschan, Daniel ^c   Goligorsky, Michael S ^c   Bachmann, Sebastian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

ADMA; Endothelial dysfunction; Interstitial scarring; L NMMA

Indexed keywords

COLLAGEN TYPE 18; DRINKING WATER; ENDOSTATIN; LIPOFUSCIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY BASEMENT MEMBRANE; CELL ACTIVITY; CELL INFILTRATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXTRACELLULAR MATRIX; FIBROBLAST; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY BLOOD VESSEL; KIDNEY FIBROSIS; KIDNEY MEDULLA; KIDNEY TUBULE BASEMENT MEMBRANE; KIDNEY TUBULE DISORDER; LEUKOCYTE; MICROMORPHOLOGY; MICROVASCULATURE; MOUSE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; TUBULOINTERSTITIAL DISEASE; UPREGULATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; KIDNEY; KIDNEY DISEASE; PATHOLOGY; THROMBOCYTE AGGREGATION; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; KIDNEY; KIDNEY DISEASES; LEUKOCYTES; MICE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; PLATELET AGGREGATION;

EID: 54449085771     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00071.2008     Document Type: Article

References (60)

1. Abu-Soud H, Feldman P, Clark P, Stuehr D. Electron transfer in the nitric oxide synthases. Characterization of L-arginine analogs that block heme iron reduction. J Biol Chem 269: 32318-32326, 1994.
2. Achan V, Broadhead M, Malaki M, Leiper J, MacAllister R, Vallance P. ADMA causes hypertension and cardiac dysfunction in humans and is actively metabolized by DDAH. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003.
3. Aisaka K, Gross F, Griffith OW, Levi R. L-Arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo. Biochem Biophys Res Commun 163: 710-717, 1989.
4. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 160: 881-886, 1989.
5. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
6. Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann NY Acad Sci 947: 93-109, 2001.
7. Birks EJ, Yacoub MH. The role of nitric oxide and cytokines in heart failure. Coron Artery Dis 8: 389-402, 1997.
8. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney. Am J Nephrol 7: 421-433, 1987.
9. Brenner B. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 110: 1753-1758, 2002.
10. Câmpean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 285: F19-F32, 2003.
11. Chau Y, Lin S, Chen J, Tai M. Endostatin induces autophagic cell death in Eahy926 human endothelial cells. Histol Histopathol 18: 715-726, 2003.
12. Drexler H, Kästner S, Strobel A, Studer R, Brodder OE, Hasenfuss F. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 32: 955-963, 1998.
13. Durvasula R, Shankland S. Models of glomerulonephritis. In: Renal Disease Techniques and Protocols, edited by Goligorsky MS. Totowa, NJ: Humana, 2003, p. 47-66.
14. Eddy A. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
15. Eitner F, Floege J. Novel insights into renal fibrosis. Curr Opinion Nephrol Hypertens 12: 227-232, 2003.
16. Erdely A, Wagner L, Muller V, Szabo A, Baylis C. Protection of Wistar-Furth rat from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 14: 2526-2533, 2003.
17. Fogo A. Renal fibrosis and the renin-angiotensin system. Adv Nephrol Necker Hosp 31: 69-87, 2001.
18. Goligorsky MS. Endothelial cell dysfunction and nitric oxide synthase. Kidney Int 58: 1360-1376, 2000.
19. Goligorsky MS, Abedi H, Noiri E, Tachtajan A, Lense S, Romanov VI, Zachary I. Nitric oxide modulation of focal adhesions in endothelial cells. Am J Physiol Cell Physiol 276: C1271-C1281, 1999.
20. Goligorsky MS, Noiri E, Tsukahara H, Budzikowski A, Li H. A pivotal role of nitric oxide in endothelial cell dysfunction. Acta Physiol Scand 168: 33-41, 2000.
21. Gschwend S, Buikema H, Navis G, Henning R, DeZeeuw D, van Dokkum R. Endothelial dilatory function predicts individual susceptibility to renal damage in 5/6 nephrectomized rat. J Am Soc Nephrol 13: 2909-2915, 2002.
22. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90: 1110-1115, 1992.
23. Igarashi J, Michel T. More sweetness than light? A search for the causes of diabetic vasculopathy. J Clin Invest 108: 1425-1427, 2001.
24. Kang D, Joly A, Oh S, Johnson R. Impaired angiogenesis in the remnant kidney model. J Am Soc Nephrol 12: 1434-1447, 2001.
25. Kang D, Joly A, Mazali M, Johnson R. Impaired angiogenesis in the remnant kidney model. J Am Soc Nephrol 12: 1448-1457, 2001.
26. Kang D, Kanellis J, Hugo C, Johnson R. Role of microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13: 806-816, 2002.
27. Kang D, Nakagawa T, Feng L, Johnson R. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
28. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opinion Nephrol Hypertens 12: 25-29, 2003.
29. Lee L, Meyer T, Pollock A, Lovett D. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96: 953-964, 1995.
30. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem 274: 17325-17333, 1999.
31. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 9: 521-530, 2003.
32. Mordvintsev PI, Rudneva VG, Vanin AF, Shimkevich LL, Khodorov BI. Inhibition of platelet aggregation by dinitrosyl iron complexes with low molecular weight ligands. Biokhimiia 51: 1851-1857, 1986.
33. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60: 1077-1082, 2001.
34. Nakagawa T, Kang D, Ohashi R, Suga S, Herrera-Acosta J, Rodriguez-Iturbe B, Johnson R. Tubulointerstitial disease: role of ischemia and microvascular disease. Curr Opinion Nephrol Hypertens 12: 233-241, 2003.
35. Nava E, Farré AL, Moreno C, Casado S, Mareau P, Cosentino F, Lüscher TF. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens 16: 609-615, 1998.
36. Noiri E, Lee E, Testa J, Quigley J, Colflesh D, Keese C, Giaever I, Goligorsky MS. Podokinesis in endothelial cell migration: role of NO. Am J Physiol Cell Physiol 274: C236-C244, 1998.
37. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 97: 2494-2498, 1998.
38. Ohashi R, Kitamura H, Yamanaka N, Johnson R. Peritubular capillary injury during progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 11: 47-56, 2000.
39. Ohashi R, Shimizu A, Masuda Y, Johnson R. Peritubular capillary regression during progression of experimental obstructive nephropathy. J Am Soc Nephrol 13: 1795-1805, 2002.
40. O'Reiley M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
41. O'Riordan E, Mendelev N, Patschan S, Patschan D, Eskander J, Cohen-Gould L, Chander P, Goligorsky MS. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 292: H285-H294, 2007.
42. Paliege A, Pasumarthy A, Mizel D, Yang T, Schnerrmann J, Bachmann S. Effect of apocynin treatment on renal expression of COX-2, NOS1, and renin in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 290: R694-R700, 2006.
43. Papapetropoulos A, Garcia-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100: 3131-3139, 1997.
44. Patschan S, Chen J, Polotskaia A, Mendelev N, Cheng J, Patschan D, Goligorsky MS. Lipid mediators of autophagy in stress-induced premature senescence of endothelial cells. Am J Physiol Heart Circ Physiol 294: H1119-H1129, 2008.
45. Peters H, Daig U, Martini S, Ruckert M, Schaper F, Liefeldt L, Kramer S, Neumayer H. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int 64: 509-518, 2003.
46. Prabhakar SS. L-Arginine-nitric oxide pathway in end-stage renal disease. Am J Kidney Dis 39: 195-198, 2002.
47. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, Bauer C, Theilig F, Bachmann S, Kraemer-Guth A, Wanner C, Theuring F, Galle F, Hocher B. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/ endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 18: 730-740, 2007.
48. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058, 1987.
49. Schanstra J, Neau E, Drogoz P, Gomez M, Lopez-Novoa J, Calise D, Pecher C, Bader M, Girolami J, Bascands J. In vivo bradikinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379, 2002.
50. Smirnova I, Kajstura M, Sawamura T, Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: the role in foam cell formation. Am J Physiol Heart Circ Physiol 287: H782-H790, 2004.
51. Smirnova I, Sawamura T, Goligorsky MS. Upregulation of lectin-like oxidized LDL receptor-1 (LOX-1) in endothelial cells by NO deficiency. Am J Physiol Renal Physiol 287: F25-F32, 2004.
52. Stroikin Y, Dalen H, Loof S, Terman A. Inhibition of autophagy with 3-methyladenine results in impaired turnover of lysosomes and accumulation of lipofuscin-like material. Eur J Cell Biol 83: 583-590, 2004.
53. Valkonen V, Palva H, Salonen J, Lakka T. Risk of acute coronary events and serum concentration of ADMA. Lancet 358: 2127-2128, 2001.
54. Vallance P. Importance of ADMA in cardiovascular risk. Lancet 358: 2096-2097, 2001.
55. Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res 23: 1053-1057, 1989.
56. Vallance P, Leiper J. Cardiovascular biology of ADMA: DDAH pathway. Arterioscler Thromb Vasc Biol 24: 1023-1030, 2004.
57. Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollmann MJ, Gibbons GH, Tsao PS, Cooke JP. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 99: 1236-1241, 1999.
58. Waschke J, Burger S, Curry F, Drenckhahn D, Adamson RH. Activation of Rac-1 and Cdc42 stabilizes the microvascular endothelial barrier. Histochem Cell Biol 125: 397-406, 2006.
59. Zoccali C, Bode-Boger S, Mallamaci F, Boger R. Plasma concentration of ADMA and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117, 2001.
60. Zoja C, Benigni A, Camozzi D, Corna D, Longaretti L, Todeschini M, Remuzzi G. Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney Int 64: 857-863, 2003.